Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
BLC661
Bladder cancer tissue array, 66 cores including bladder cancers (29 cases) and uninvolved bladder tissues (4 cases) in duplicates, with grading and TNM staging data.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$307
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
G | |
H | |









TNM Classification : Urinary bladder carcinoma
T Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Ta Noninvasive papillary carcinoma
Tis Carcinoma in situ: "flat carcinoma"
T1 Tumor invades subepithalial connective tissue
T2 Tumor invades muscle
T2a Tumor invades superficial muscle (inner half)
T2b Tumor invades deep muscle (outer half)
T3 Tumor invades perivesical tissue
T3a microscopically
T3b macroscopically (extravesical mass)
T4 Tumor directly invades any of the followings: prostate, uterus, vagina, pelvic wall,
abdominal wall
T4a Tumor invades prostate, uterus, vagina
T4b Tumor invades pelvic wall, abdominal wall
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single lymph nodes, 2 cm or less in greatest dimension
N2 Metastasis in a single lymph node more than 2 cm but not more than 5 cm in
greatest dimension; or multiple lymph nodes, none more than 5 cm in greatest
dimension
N3 Metastasis in a lymph node, more than 5 cm in greatest dimension
M Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Human
33
66
1.5mm
4um
8
9
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in various urinary bladder cancers.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | M | 71 | Bladder, urinary | Normal | |||
A02 | M | 59 | Bladder, urinary | Normal | |||
A03 | M | 47 | Bladder, urinary | Chronic cystitis* | |||
A04 | F | 51 | Bladder, urinary | Chronic cystitis | |||
A05 | M | 71 | Bladder, urinary | Squamous cell carcinoma | I~II | T2N0M0 | |
A06 | M | 60 | Bladder, urinary | Squamous cell carcinoma | I | T2N0M0 | |
A07 | M | 76 | Bladder, urinary | Adenocarcinoma | I~II | T3N0M0 | |
A08 | M | 50 | Bladder, urinary | Adenocarcinoma | II | T2N0M0 | |
A09 | M | 68 | Bladder, urinary | Adenocarcinoma | III | T2N0M0 | |
B01 | M | 71 | Bladder, urinary | Normal | |||
B02 | M | 59 | Bladder, urinary | Normal | |||
B03 | M | 47 | Bladder, urinary | Chronic cystitis* | |||
B04 | F | 51 | Bladder, urinary | Chronic cystitis | |||
B05 | M | 71 | Bladder, urinary | Squamous cell carcinoma | I~II | T2N0M0 | |
B06 | M | 60 | Bladder, urinary | Squamous cell carcinoma | I | T2N0M0 | |
B07 | M | 76 | Bladder, urinary | Adenocarcinoma | I~II | T3N0M0 | |
B08 | M | 50 | Bladder, urinary | Adenocarcinoma | II | T2N0M0 | |
B09 | M | 68 | Bladder, urinary | Adenocarcinoma | III | T2N0M0 | |
C01 | F | 74 | Bladder, urinary | Adenocarcinoma | III | T2N0M0 | |
C02 | M | 27 | Bladder, urinary | Transitional cell carcinoma | I | TisN0M0 | |
C03 | M | 50 | Bladder, urinary | Transitional cell carcinoma | I | T1N0M0 | |
C04 | F | 34 | Bladder, urinary | Transitional cell carcinoma | I | T1N0M0 | |
C05 | F | 72 | Bladder, urinary | Transitional cell carcinoma | I | T1N0M0 | |
C06 | F | 51 | Bladder, urinary | Transitional cell carcinoma | II | T1N0M0 | |
C07 | M | 57 | Bladder, urinary | Transitional cell carcinoma | I | T1N0M0 | |
C08 | M | 47 | Bladder, urinary | Transitional cell carcinoma | I~II | T1N0M0 | |
C09 | M | 54 | Bladder, urinary | Transitional cell carcinoma | II | T2N0M0 | |
D01 | F | 74 | Bladder, urinary | Adenocarcinoma | III | T2N0M0 | |
D02 | M | 27 | Bladder, urinary | Transitional cell carcinoma | I | TisN0M0 | |
D03 | M | 50 | Bladder, urinary | Transitional cell carcinoma | I | T1N0M0 | |
D04 | F | 34 | Bladder, urinary | Transitional cell carcinoma | I | T1N0M0 | |
D05 | F | 72 | Bladder, urinary | Transitional cell carcinoma | I | T1N0M0 | |
D06 | F | 51 | Bladder, urinary | Transitional cell carcinoma | II | T1N0M0 | |
D07 | M | 57 | Bladder, urinary | Transitional cell carcinoma | I | T1N0M0 | |
D08 | M | 47 | Bladder, urinary | Transitional cell carcinoma | I~II | T1N0M0 | |
D09 | M | 54 | Bladder, urinary | Transitional cell carcinoma | II | T2N0M0 | |
E01 | M | 45 | Bladder, urinary | Transitional cell carcinoma | II | T2N0M0 | |
E02 | M | 74 | Bladder, urinary | Transitional cell carcinoma | II | T2N0M0 | |
E03 | M | 57 | Bladder, urinary | Transitional cell carcinoma | II | T1N0M0 | |
E04 | M | 80 | Bladder, urinary | Transitional cell carcinoma | II~III | T1N0M0 | |
E05 | F | 53 | Bladder, urinary | Transitional cell carcinoma | I~II | T1N0M0 | |
E06 | M | 37 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
E07 | M | 65 | Bladder, urinary | Transitional cell carcinoma | I~II | T3N0M0 | |
E08 | M | 52 | Bladder, urinary | Transitional cell carcinoma | II | T1N0M0 | |
E09 | M | 78 | Bladder, urinary | Transitional cell carcinoma | II~III | T2N0M0 | |
F01 | M | 45 | Bladder, urinary | Transitional cell carcinoma | II | T2N0M0 | |
F02 | M | 74 | Bladder, urinary | Transitional cell carcinoma | II | T2N0M0 | |
F03 | M | 57 | Bladder, urinary | Transitional cell carcinoma | II | T1N0M0 | |
F04 | M | 80 | Bladder, urinary | Transitional cell carcinoma | II~III | T1N0M0 | |
F05 | F | 53 | Bladder, urinary | Transitional cell carcinoma | I~II | T1N0M0 | |
F06 | M | 37 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
F07 | M | 65 | Bladder, urinary | Transitional cell carcinoma | I~II | T3N0M0 | |
F08 | M | 52 | Bladder, urinary | Transitional cell carcinoma | II | T1N0M0 | |
F09 | M | 78 | Bladder, urinary | Transitional cell carcinoma | II~III | T2N0M0 | |
G01 | M | 64 | Bladder, urinary | Transitional cell carcinoma | III | T3N2M1 | |
G02 | M | 70 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
G03 | M | 61 | Bladder, urinary | Transitional cell carcinoma | III | T3N0M0 | |
G04 | M | 61 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
G05 | F | 39 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
G06 | M | 30 | Bladder, urinary | Sarcoma | |||
H01 | M | 64 | Bladder, urinary | Transitional cell carcinoma | III | T3N2M1 | |
H02 | M | 70 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
H03 | M | 61 | Bladder, urinary | Transitional cell carcinoma | III | T3N0M0 | |
H04 | M | 61 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
H05 | F | 39 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
H06 | M | 30 | Bladder, urinary | Sarcoma | |||
null |